ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

In the current study, published today in the journal Nature Biotechnology, Cheng and his colleagues created an exosome system that co-displays two therapeutic proteins to treat lung metastases. One ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

Use of immune checkpoint inhibitors for cancer was associated with a significant reduction in actinic keratoses in a small study. The effect was greatest in younger patients and those with a history ...

Cancer represents a key challenge in medical science, manifesting as a disease where the immune system fails to recognize and eliminate tumor cells. The phenomenon of immune evasion by cancer cells ...

New data show hip osteoarthritis does not raise the risk of immune checkpoint inhibitor–induced inflammatory arthritis, while ...

MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...

Please provide your email address to receive an email when new articles are posted on . Current therapies do not prevent the onset of new lesions within a field of cancerization. Immune checkpoint ...